以分子表征运动对减轻新辅助治疗(NAT)引起的胰腺导管腺癌(PDAC)患者的身体下降的影响,在个性化运动干预之前和之后,我们采用了多组学方法对血浆样本进行分析.由个性化的有氧和抗阻运动组成,这种干预与显著的分子变化相关,这些变化与瘦体重的改善相关,阑尾骨骼肌指数(ASMI),以及在400米步行测试(MWT)和坐立测试中的性能。这些改变表明运动诱导的炎症和线粒体功能标记的调节。本案例研究提供了基于多组学的监督锻炼评估的主要应用证明,从而支持这种干预作为PDAC患者的可行和有益的干预措施,潜在地提高治疗反应和患者生活质量。这里观察到的分子变化强调了身体活动在癌症治疗方案中的重要性,倡导为癌症患者开发可访问的多组学指导运动计划。
To molecularly characterize the impact of exercise on mitigating neoadjuvant treatment (NAT)-induced physical decline in pancreatic ductal adenocarcinoma (PDAC) patients, a multi-omics approach was employed for the analysis of plasma samples before and after a personalized exercise intervention. Consisting of personalized aerobic and resistance exercises, this intervention was associated with significant molecular changes that correlated with improvements in lean mass, appendicular skeletal muscle index (ASMI), and performance in the 400-m walk test (MWT) and sit-to-stand test. These alterations indicated exercise-induced modulation of inflammation and mitochondrial function markers. This
case study provides proof-of-principal application for multiomics-based assessments of supervised exercise, thereby supporting this intervention as a feasible and beneficial intervention for PDAC patients to potentially enhance treatment response and patient quality of life. The molecular changes observed here underscore the importance of physical activity in cancer treatment protocols, advocating for the development of accessible multiomics-guided exercise programs for cancer patients.